Abstract:Abstract Background Studies have reported conflicting findings regarding the effect of timing of biologics initiation on disease course, often affected by selection and referral biases. In this nationwide cohort study we aimed to explore whether early initiation of biologics is associated with better disease outcomes in CD and UC. Methods Data of patients diagnosed with IBD in the epi-IIRN cohort from 2005 to 2020 were retrieved from 4 Israeli Health-Maintenance-Organizations covering 98% of the population.The primary analysis was time to steroid-dependency and IBD-related surgery. To control for confounding by indication in which the severity of disease could account both for the timing of biologics and risk of disease outcomes,we compared treatment strategies using the cloning,censoring and weighting method to emulate a target trial. Inverse probability of treatment weights were fitted per patient to adjust by weighting for time varying confounding and selection bias.Survival probabilities(POS) were estimated and compared at 10 years post diagnosis for each strategy through weighted non-parametric Kaplan-Meier estimators. The 95%CIs for survival probabilities were calculated using non-parametric bootstrap with 500 replicates. Results Of the 34,375 patients diagnosed with IBD, 7,452(39%) CD patients and 2,235(15%) UC patients received biologics and included in the analysis. In total,1,139 CD and 206 UC patients received biologics during the first three months after diagnosis,2,108 CD and 450 UC during the 3-12 month period,1,161 CD and 396 UC during 1-2 year period,and 719 CD and 271 UC during 2-3 years post diagnosis. Patients who initiated biologics after 3 years post diagnosis were excluded as they were not considered early biologics initiation.In CD,at 10 years post diagnosis there was a significant but modest decrease in IBD-related surgeries when initiating biologics prior to 3 months compared to the other periods (POS:0-3 months 0.75[CI 0.71- 0.79] vs 2-3 year 0.7[CI 0.66-0.73] ;p<0.05).The same observation with a larger effect, was apparent for steroid-dependency (POS:0-3 months 0.78[CI 0.75-0.82] vs 2-3 year 0.69[CI 0.66-0.71]; p<0.001)(Fig 1). In UC, no significant differences in colectomy rate at 10 years was observed between the treatment periods (POS:0-3 months 0.92[CI 0.87-0.97] vs. 2-3 years 0.94[CI 0.91-0.98];p=0.42). On the other hand, a significant decrease was apparent for steroid-dependency (POS:0-3 months 0.78[CI 0.75-0.82] vs 2-3 year 0.69[CI 0.66-0.71];p<0.001)(Fig 2). Conclusion Our study showed a slight advantage to earlier initiation of biologics,as reflected by longer time to IBD-related surgery and steroid-dependency in CD.In UC, the effect of early biologics was minor and was only apparent for steroid dependency in UC.

P271 Impact of Biologics on Surgical Trends in Inflammatory Bowel Disease: Insights from a Lower-endemic Region

P855 Have biological agents changed the need for abdominal surgery in inflammatory bowel disease over time?

Temporal trends in surgery for Crohn’s disease: A ten-year single-center retrospective study

Laparoscopic Surgery Contributes to a Decrease in Short-Term Complications in Surgical Ulcerative Colitis Patients During 2008-2017: a Multicenter Retrospective Study in China

Safety of perioperative treatment with biologics in patients with inflammatory bowel disease undergoing bowel surgery: Experience from a large urban center

Initial medical and surgical management of inflammatory bowel disease in the biologic era: A comparison between the United States and China

OP12 Does early initiation of biologics change the natural history of IBD? a nationwide study from the epi-IIRN

Impact of antitumour necrosis factor therapy on surgery in inflammatory bowel disease: a population-based study

OP35 Treatment outcomes of inflammatory bowel disease in the biological era—a nationwide retrospective cohort study in three Nordic countries: Results from the TRINordic study

P479 Trends in Medication Use and Treatment Patterns in Chinese Patients with Inflammatory Bowel Diseases: A Multicenter Cohort Study from 1999 to 2020

P907 Impact of preoperative use of biologics on 30-day surgical morbidity and mortality in patients with Crohn’s Disease undergoing ileocolectomy: National Surgical Quality Improvement Program database analysis

Changing trends in surgery for abdominal Crohn's disease

P666 Trend of Lower gastrointestinal Endoscopy in Patients with Inflammatory Bowel Diseases: A Nationwide Population-Based Study in South Korea

Current Status and Trends in Inflammatory Bowel Disease Surgery in Korea: Analysis of Data in a Nationwide Registry

Temporal Changes in the Treatment Paradigm and Long-term Prognosis of Patients With Crohn's Disease: A Hospital-Based Cohort Study in China

P347 A Trend Analysis of Inflammatory Bowel Disease in Non-Endemic Era (1993-2023)

P416 Turning Point: Declining surgery rates and predictors for surgery in a three-year prospective inception cohort of Crohn's Disease in China

Crohn's disease after surgery: Changes in post‐operative management strategies over time and their impact on long‐term re‐operation rate—A retrospective multicentre real‐world study

Treatment strategy changes for inflammatory bowel diseases in biologic era: results from a multicenter cohort in Japan, Far East 1000